Publications
Detailed Information
Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Chang Kyung | - |
dc.contributor.author | Shin, Hyun Mu | - |
dc.contributor.author | Choe, Pyoeng Gyun | - |
dc.contributor.author | Park, Jiyoung | - |
dc.contributor.author | Hong, Jisu | - |
dc.contributor.author | Seo, Jung Seon | - |
dc.contributor.author | Lee, Yung Hie | - |
dc.contributor.author | Chang, Euijin | - |
dc.contributor.author | Kim, Nam Joong | - |
dc.contributor.author | Kim, Minji | - |
dc.contributor.author | Kim, Yong-Woo | - |
dc.contributor.author | Kim, Hang-Rae | - |
dc.contributor.author | Lee, Chang-Han | - |
dc.contributor.author | Seo, Jun-Young | - |
dc.contributor.author | Park, Wan Beom | - |
dc.contributor.author | Oh, Myoung-Don | - |
dc.date.accessioned | 2024-04-26T00:58:28Z | - |
dc.date.available | 2024-04-26T00:58:28Z | - |
dc.date.created | 2022-05-24 | - |
dc.date.created | 2022-05-24 | - |
dc.date.issued | 2022-05 | - |
dc.identifier.citation | BMC Medicine, Vol.20 No.1, p. 181 | - |
dc.identifier.issn | 1741-7015 | - |
dc.identifier.uri | https://hdl.handle.net/10371/199581 | - |
dc.description.abstract | Background Practical guidance is needed regarding the vaccination of coronavirus disease 2019 (COVID-19) convalescent individuals in resource-limited countries. It includes the number of vaccine doses that should be given to unvaccinated patients who experienced COVID-19 early in the pandemic. Methods We recruited COVID-19 convalescent individuals who received one or two doses of an mRNA vaccine within 6 or around 18 months after a diagnosis of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection. Their samples were assessed for IgG-binding or neutralizing activity and cell-mediated immune responses against SARS-CoV-2 wild-type and variants of concern. Results A total of 43 COVID-19 convalescent individuals were analyzed in the present study. The results showed that humoral and cellular immune responses against SARS-CoV-2 wild-type and variants of concern, including the Omicron variant, were comparable among patients vaccinated within 6 versus around 18 months. A second dose of vaccine did not significantly increase immune responses. Conclusion One dose of mRNA vaccine should be considered sufficient to elicit a broad immune response even around 18 months after a COVID-19 diagnosis. | - |
dc.language | 영어 | - |
dc.publisher | BioMed Central | - |
dc.title | Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection | - |
dc.type | Article | - |
dc.identifier.doi | 10.1186/s12916-022-02383-4 | - |
dc.citation.journaltitle | BMC Medicine | - |
dc.identifier.wosid | 000790761000002 | - |
dc.identifier.scopusid | 2-s2.0-85129356732 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 181 | - |
dc.citation.volume | 20 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Shin, Hyun Mu | - |
dc.contributor.affiliatedAuthor | Kim, Nam Joong | - |
dc.contributor.affiliatedAuthor | Kim, Hang-Rae | - |
dc.contributor.affiliatedAuthor | Lee, Chang-Han | - |
dc.contributor.affiliatedAuthor | Park, Wan Beom | - |
dc.contributor.affiliatedAuthor | Oh, Myoung-Don | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | IMMUNODEFICIENCY-VIRUS TYPE-1 | - |
dc.subject.keywordPlus | VPR | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | Vaccination | - |
dc.subject.keywordAuthor | Immune response | - |
dc.subject.keywordAuthor | mRNA | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.